Advanced Search

Journal of Traditional Chinese Medicine >

2022 , Vol. 42 >Issue 1: 108 - 115

DOI: https://doi.org/10.19852/j.cnki.jtcm.2022.01.007

Research Articles

Mechanism underlying the effect of Liujunzi decoction (六君子汤) on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy

  • Xiaoli XIN ,
  • Guodong WANG ,
  • Ru HAN ,
  • Yi JIANG ,
  • Chang LIU ,
  • Lingshuang LIU ,
  • Zhenye XU
Expand
  • 1 Department of Oncology, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    2 Department of Orthopedics, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 20032, China
    3 Department of human resources, Shandong Academy of Occupational Health and Occupational Medicine, Jinan 250000, China
XU Zhenye, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. xuzhenye1947@126.com
LIU Lingshuang, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. liuls107@163.com;

Received date: 2021-02-22

  Accepted date: 2021-05-14

  Online published: 2022-01-25

Supported by

National Natural Science Foundation of China (NSFC) (Therapeutic Effect and Mechanism of Embryonic Lung Progenitor Cell Transplantation on Silicosis Fibrosis)(81903270);National Natural Science Foundation of China (NSFC) (Study on the Synergistic Effect and Mechanism of Yiqi Yangyin Jiedu Prescription Combined with Anti-CTLA-4 Mab in Inducing Anti-Lung Cancer Immune Response)(81703987);Jinan Science and Technology Project(Study of Therapy and Mechanisms of Embryonic Lung Stem Cell Transplantation on Silicosis Fibrosis)(201907019);Shanghai Science and Technology Commission (a Multicenter Randomized Controlled Study on Improving Prognosis of Patients With Stage ⅢA Non-Small Cell Lung Cancer By Liu Jiaxiang's Prescription for Qi-Yin Differentiation and Treatment)(19401971200);Emerging Frontier Technology Joint Research Project of Shanghai Shenkang Hospital Development Center (a Multicenter Randomized Controlled Double-Blind Study on the Prevention and Treatment of Postoperative Recurrence and Metastasis Of Stage ⅢA Non-Small Cell Lung Cancer By Liu Jiaxiang Qi-Yin Differentiation Method)(SHDC12018131);Major Project of Scientific Research and Innovation Plan of Shanghai Education Commission (Study on the Mechanism of Feyanning Prescription Against Lung Cancer Growth and Metastasis Derived from Jingqi Theory)(2017-01-07-00-10-E00064);Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (Clinical Study of Yiqi Yangyin Jiedu Prescription Combined With Oxitinib in the Treatment of Advanced Lung Cancer With T790M Mutation)(AJ-37);Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (Clinical Study of “Decubitus Chiropractic Therapy” in the Treatment of Vertebral Artery Type Cervical Spondylosis)(AJ-41);National Traditional Chinese Medicine Clinical Research Base Long-Yi-Xue-Zhe Nurturing Plan (Mechanism of Reversal of EGFR-Tkis Resistance Induced By HGF in Tumor-Bearing H1975-SCID Mice Based on Huachansu Injection)(LYTD-64)

Fold

Abstract

OBJECTIVE: To further clarify the anticancer mechanisms of Liujunzi decoction (六君子汤) and provide possible targets for the treatment of advanced-stage non-small cell lung cancer (NSCLC) by re-analyzing differential gene expression profile of peripheral blood mononuclear cells (PBMCs) from Liujunzi decoction-treated NSCLC patients receiving first-line chemotherapy.

METHODS: The PBMC gene expression microarray data set GSE61926 was retrieved from a high throughput gene expression database. Differentially expressed genes (DEGs) were screened by paired sample t-test and the multiple ratio method. Gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses were performed using the DAVID database. The protein–protein interaction (PPI) network was constructed using interaction gene library retrieval tools and Cytoscape software.

RESULTS: A total of 162 DEGs were identified, with 67 upregulated genes and 95 downregulated genes. The functional distribution of Gene Oncology (GO) genes showed that DEGs were mostly concentrated in extracellular regions, calcium ion binding, and transcriptase activity. KEGG pathway analysis showed that cytokine–cytokine receptor interactions were significantly enriched. PPI network analysis screened out the top 10 central protein-coding genes with the highest nodal degree: IL2, PIWIL4, DICER1, PIWIL2, SAA1, XCL1, IL22RA1, ARHGAP11A, DCP1A, and GDNF. Among them, the central protein-coding gene with the highest node degree was IL2. In addition, the central protein-coding genes with high node degrees and high molecular complex detection (MCODE) scores were PIWIL4, DICER1, PIWIL2, and DCP1A, all of which are related to tumor development.

CONCLUSIONS: One signaling pathway and 10 central protein-coding genes related to anticancer mechanisms were screened by re-analysis of GSE61926 data. IL2, PIWIL4, DICER1, PIWIL2, and DCP1A may have important roles in the mechanism of Liujunzi decoction treatment against NSCLC. Our results suggest that the anticancer mechanism of Liujunzi decoction may be related to gene silencing by RNA and the biological processes of piwi-interacting RNA and other small RNAs.

Key words： carcinoma; non-small-cell lung; antineoplastic agents; computational biology; RNA; small interfering; Liujunzi decoction

Cite this article

Xiaoli XIN , Guodong WANG , Ru HAN , Yi JIANG , Chang LIU , Lingshuang LIU , Zhenye XU . Mechanism underlying the effect of Liujunzi decoction (六君子汤) on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy[J]. Journal of Traditional Chinese Medicine, 2022 , 42(1) : 108 -115 . DOI: 10.19852/j.cnki.jtcm.2022.01.007

References

[1] Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017;389:299-311.
[2] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
[4] Chen D, Zhao J, Cong W. Chinese herbal medicines facilitate the control of chemotherapy-induced side effects in colorectal cancer: progress and perspective. Front Pharmacol 2018;9:1442.
[5] Sun LL, Lai HZ, Chen ZZ, et al. Modified Liujunzi decoction alleviates chemotherapy-induced anorexia in advanced non-small cell lung cancer: a propensity score matched case-control study. Chin J Integr Med 2020;26:256-62.
[6] Hirose C, Iihara H, Funaguchi N, et al. Prophylactic effect of rikkunshito, an herbal medicine, for chemotherapy-induced nausea in thoracic cancer patients receiving carboplatin-based chemotherapy. Pharmazie 2019; 74620-624.
[7] Chen YC, Lin AS, Hung YC, et al. Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy. Exp Ther Med 2017;14:2040-52.
[8] Kang HJ, Jeong MK, Park SJ, et al. Efficacy and safety of Yukgunja-Tang for treating anorexia in patients with cancer: the protocol for a pilot, randomized, controlled trial. Medicine (Baltimore) 2019;98:e16950.
[9] Ohnishi S, Watari H, Kanno M, et al. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase Ⅱ study (JORTC KMP-02). J Gynecol Oncol 2017;28:e44.
[10] Morishige KI. Traditional herbal medicine, Rikkunshito, for chemotherapy-induced nausea and vomiting. J Gynecol Oncol 2017;28:e57.
[11] Terawaki K, Kashiwase Y, Sawada Y, et al. Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model. PLoS One 2017;12:e0173113.
[12] Tominaga K, Kido T, Ochi M, et al. The traditional Japanese medicine rikkunshito promotes gastric emptying via the antagonistic action of the 5-HT(3) receptor pathway in rats. Evid Based Complement Alternat Med 2011;2011:248481.
[13] Kanda R, Miyagawa Y, Wada-Hiraike O, et al. Rikkunshito attenuates induction of epithelial-mesenchymal switch via activation of Sirtuin1 in ovarian cancer cells. Endocr J 2020;67:379-86.
[14] Kiartivich S, Wei Y, Liu J, et al. Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells. Oncol Lett 2017;13:2799-804.
[15] Deng X, Liu J, Liu L, et al. Drp1-mediated mitochondrial fission contributes to baicalein-induced apoptosis and autophagy in lung cancer via activation of AMPK signaling pathway. Int J Biol Sci 2020;16:1403-16.
[16] Cathcart MC, Useckaite Z, Drakeford C, et al. Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo. BMC Cancer 2016;16:707.
[17] Hu CY, Zhang YH, Wang T, et al. Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer. Clin Exp Immunol 2016;186:106-14.
[18] Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer [published correction appears in Immunity 2019 Aug 20; 51(2): 411-412]. Immunity 2018;48: 812-30.e14.
[19] Zhang W, Li M, Du W, et al. Tissue distribution and anti-lung cancer effect of 10-hydroxycamptothecin combined with Platycodonis Radix and Glycyrrhizae Radix ET Rhizoma. Molecules 2019;24:2068.
[20] Li W, Gao LN, Song PP, et al. Development and validation of a RNA binding protein-associated prognostic model for lung adenocarcinoma. Aging (Albany NY) 2020;12:3558-73.
[21] Navarro A, Tejero R, Vi?olas N, et al. The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer. Oncotarget 2015;6:31544-56.
[22] Schultz KAP, Stewart DR, Kamihara J, et al. DICER1 tumor predisposition. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews?. Seattle (WA): University of Washington, Seattle; April 24, 2014:1-34.
[23] Tan Y, Liu L, Liao M, et al. Emerging roles for PIWI proteins in cancer. Acta Biochim Biophys Sin 2015;47:315-24.
[24] Qu X, Liu J, Zhong X, Li X, Zhang Q. PIWIL2 promotes progression of non-small cell lung cancer by inducing CDK2 and Cyclin A expression. J Transl Med 2015;13:301.
[25] Maleki Dana P, Mansournia MA, Mirhashemi SM. PIWI-interacting RNAs: new biomarkers for diagnosis and treatment of breast cancer. Cell Biosci 2020;10:44.
[26] Yao J, Wang YW, Fang BB, Zhang SJ, Cheng BL. piR-651 and its function in 95-D lung cancer cells. Biomed Rep 2016;4:546-50.
[27] Peng L, Song L, Liu C, et al. piR-55490 inhibits the growth of lung carcinoma by suppressing mTOR signaling. Tumour Biol 2016;37:2749-56.
[28] Fathizadeh H, Asemi Z. Epigenetic roles of PIWI proteins and piRNAs in lung cancer. Cell Biosci 2019;9:102.
[29] Balatti V, Nigita G, Veneziano D, et al. tsRNA signatures in cancer. Proc Natl Acad Sci U S A 2017;114:8071-76.
[30] Chalbatani GM, Dana H, Memari F, et al. Biological function and molecular mechanism of piRNA in cancer. Pract Lab Med 2018;13:e00113.
[31] Kim J, Field A, Schultz KAP, Hill DA, Stewart DR. The prevalence of DICER1 pathogenic variation in population databases. Int J Cancer 2017;141:2030-6.
[32] Stewart DR, Best AF, Williams GM, et al. Neoplasm risk among individuals with a pathogenic germline variant in DICER1. J Clin Oncol 2019;37:668-76.
[33] Prodromaki E, Korpetinou A, Giannopoulou E, et al. Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas. Cell Oncol (Dordr) 2015;38:307-17.
[34] Huang SQ, Sun B, Xiong ZP, et al. The dysregulation of tRNAs and tRNA derivatives in cancer. J Exp Clin Cancer Res 2018;37:101.
Options
Outlines

/

〈 〉